Meeker David P 4
4 · Trevi Therapeutics, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Trevi Therapeutics (TRVI) Director David Meeker Receives Option Award
What Happened
- David P. Meeker, a director of Trevi Therapeutics (TRVI), was granted an option award covering 35,000 shares on June 3, 2026. The filing reports the acquisition as a derivative award with a reported price of $0.00 and $0 total in the Form 4 entry. This is an award (A), not a purchase or sale.
Key Details
- Transaction date: June 3, 2026; Form 4 filed June 4, 2026 (appears timely).
- Instrument: Option award (derivative) for 35,000 shares reported at $0.00.
- Vesting: The option is scheduled to fully vest on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to Meeker’s continued service (per footnote).
- Shares owned after transaction: Not specified in the provided filing details.
- No indication of a sale, exercise, tax withholding, or 10b5-1 plan in this filing.
Context
- This is a compensation-related option grant to a director. It is not an exercised option or an open-market purchase or sale, and does not by itself signal an immediate buy or sell action. Vesting is service-conditional and could lapse if the director leaves before vesting.
Insider Transaction Report
Form 4
Meeker David P
Director
Transactions
- Award
Nonstatutory Stock Option (right to buy)
[F1]2026-06-03+35,000→ 35,000 totalExercise: $13.45Exp: 2036-06-02→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Signature
/s/ Christopher Galletta, attorney-in-fact|2026-06-04